Comparison of cilostazol versus ticlopidine therapy after stent implantation

Seong Wook Park, Cheol Whan Lee, Hyun Sook Kim, Hyo Jung Lee, Hoon Ki Park, Myeong Ki Hong, Jae Joong Kim, Seung Jung Park

Research output: Contribution to journalArticlepeer-review

68 Citations (Scopus)


The aim of this study was to evaluate the efficacy of cilostazol for prevention of stent thrombosis compared with ticlopidine. Cilostazol is a potent antiplatelet agent with less serious side effects. However, few data are available about the effect of cilostazol in preventing stent thrombosis after coronary stent implantation. Four hundred ninety patients selected for elective stent placement were randomized to receive aspirin plus ticlopidine (n = 243) or aspirin plus cilostazol (n = 247) for 1 month. Clinical and laboratory evaluations were performed at regular interval. There were no differences in baseline characteristics between the 2 groups. During the first 30 days after stent implantation, major cardiac events or adverse drug effects were similar between the 2 groups: ticlopidine (2.9%) vs cilostazol (1.6%) group, p = NS; stent thrombosis (0.4% vs 0.8%, p = NS, respectively), myocardial infarction (0.4% vs 0.8%, p = NS), severe leukopenia (1.2% vs 0%, p = NS), severe thrombocytopenia (0.4% vs 0%, p = NS), and cerebral hemorrhage (0.4% vs 0 %, p = NS). Adverse effects led to drug withdrawal in 7 patients in the ticlopidine group (2.9%) and in 5 in the cilostazol group (2.0%). There was no death during the follow-up period. Thus, aspirin plus cilostazol may be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine after elective coronary stenting. Copyright (C) 1999 Excerpta Medica Inc.

Original languageEnglish
Pages (from-to)511-514
Number of pages4
JournalAmerican Journal of Cardiology
Issue number5
Publication statusPublished - 1999 Sept 1

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Comparison of cilostazol versus ticlopidine therapy after stent implantation'. Together they form a unique fingerprint.

Cite this